Thomson Reuters Names Drugs to Watch in 2014
Thomson Reuters names three potential drugs anticipated to bring in over $1 billion in sales through 2019.
Thomson Reuters released its annual forecast of the leading drugs to watch in 2014, including three potential treatments anticipated to bring in more than $1 billion in sales through 2019. The analysis identified three drugs that are predicted to significantly impact the marketplace in the upcoming year.
The first drug, Sovaldi by Gilead, is an oral NS5B ploymersase inhibitor for treating hepatitis C, which is expected to reach $2.4 billion in sales in 2014, and an estimated $9.1 billion by 2019. The second is Anoro Ellipta by GSK, which contains two bronchodilators for the long-term, once-daily maintenance treatment of airflow obstruction in patients with COPD, with predicted sales of $3 billion through 2019. The third is Idelalisib by Gilead, an oral P13K p110-delta subunit inhibitor for indolent non-Hodgkin’s lymphoma in the US and chronic lymphocytic leukemia (CLL) in the UK. This treatment demonstrated effectiveness in a phase III CLL trial, however, idelalisib faces competition in the CLL marketplace.
The forecast cited other notable drugs including Eli Lilly’s long-acting GLP-1 analog dulaglutide for diabetes and its anti-VEGFR2 mAb Cyramza for gastric cancer, as well as MannKind’s inhaled insulin product Afrezza. This will be the third filing for Afrezza since 2009, after FDA twice requested further information.
The Thomson Reuters Market Insight report also includes an update on the 2013 Drugs to Watch, including Vascepa (Amarin), Pomalyst (Celgene), Kadcyla (Roche), and Relovair (GlaxoSmithKline, Thervance).
Source: Thomson Reuters
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
